Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc (LGVN) is a clinical-stage biotechnology pioneer advancing regenerative therapies through mesenchymal stem cell research. This page provides centralized access to official news and press releases for investors tracking the company's progress in treating conditions like hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and aging-related frailty.
Discover timely updates on clinical trial developments, regulatory milestones including FDA designations, and strategic partnerships. Our curated collection offers investors and researchers a reliable resource for understanding Longeveron's investigational product Lomecel-B and its applications in cellular therapeutics.
Key content includes updates on pediatric cardiac care advancements, neurodegenerative disease research breakthroughs, and manufacturing developments for allogeneic therapies. Bookmark this page to stay informed about critical updates affecting Longeveron's position in the regenerative medicine sector.
Longeveron Inc. (NASDAQ: LGVN) has commenced its Phase 2 clinical trial for Lomecel-B™ in Japan, targeting Aging-Related Frailty in the elderly population. The trial aims to enroll 45 patients and primarily focuses on assessing the safety of Lomecel-B™. Longeveron anticipates that the data collected might support limited approval under Japan's Act on the Safety of Regenerative Medicine (ASRM). The study builds on positive results from a previous U.S. trial, where patients experienced significant improvements in mobility. The trial will be conducted in collaboration with prominent medical institutions in Japan, addressing a critical need in a country with a significant aging population.
Longeveron Inc. (NASDAQ: LGVN) reported its financial results for Q4 and full year 2022, highlighting a net loss of $4.5 million in Q4, compared to $4.1 million in Q4 2021, and a total loss of $18.8 million for 2022 versus $17.0 million in 2021. Revenue for Q4 2022 was $0.1 million, down from $0.2 million in Q4 2021, largely due to fewer clinical trial participants. On a positive note, the company successfully published ELPIS I trial results in the European Heart Journal Open and initiated Phase 2 studies for Lomecel-BTM targeting aging-related frailty in Japan. They anticipate existing cash will cover expenses into H1 2024.
FAQ
What is the current stock price of Longeveron (LGVN)?
What is the market cap of Longeveron (LGVN)?
